AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease
London UK, 9 October 2023 – AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announced the completion of a £48 million ($61 million) Series A financing.